David M. Mott joined New Enterprise Associates in September 2008 as a General Partner primarily focused on biopharmaceutical investments. Dave leads NEA’s healthcare investing practice which typically comprises around 30% to 40% of each fund, or roughly $750 million to $1 billion of healthcare venture investment dollars every three to four years.  The firm invests across all stages and geographies and is a leading investor across all healthcare sectors.  Prior to joining NEA, Dave was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Dave joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and from 2000 Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he initiated and executed the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Dave founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees.  Prior to joining MedImmune, Dave was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc where he focused on public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product and device companies.  

Dave is currently Chairman of Cydan, Mersana, 3-V Biosciences, TESARO, and Zyngenia and is a director of Ardelyx, Epizyme, Omthera, and Prosensa.